Towards biomarker-driven therapies for urothelial carcinoma
S
Sara Coca Membribes
B
Bernadett Szabados
T
Thomas Powles
(Department of Medical Oncology Barts Cancer Institute Queen Mary University of London London UK)
Article Details
Journal
Nature Reviews Clinical Oncology
Volume / Issue
Vol. 23, Issue 2
Published
February 01, 2026
Pages
92-106
ISSN
1759-4774
Publisher
Springer Science and Business Media LLC
Journal Info
Nature Reviews Clinical Oncology
Springer Science and Business Media LLC
ISSN: 1759-4774 Q1 Medicine
Authors (3)
S
Sara Coca Membribes
B
Bernadett Szabados
T
Thomas Powles
Department of Medical Oncology Barts Cancer Institute Queen Mary University of London London UK
Related Articles from this Journal
Ibrutinib improves overall survival in patients with mantle cell lymphoma
Peter Sidaway
Jul 2026
10.1038/s41571-026-01166-7
First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA
Diana Romero
Jul 2026
10.1038/s41571-026-01169-4
Clinical implementation of multi-cancer early detection tests: can we find a path forward?
Ariadna Tibau, Aaron S. Kesselheim
Jul 2026
10.1038/s41571-026-01158-7
Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer
David Killock
Jul 2026
10.1038/s41571-026-01162-x
Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer
W. K. Jacky Lam, Brigette B. Y. Ma
Jul 2026
10.1038/s41571-026-01157-8